[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100321561":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":100,"collaborators":19,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":104,"sex":110,"minAge":111,"maxAge":19,"enrollmentInfo":112,"targetDuration":19,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Genethon","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GNT0003","EXPERIMENTAL","2 doses of the IMP assessed in the dose escalation, open-label, phase 1\u002F2 study",[13],"Genetic: GNT0003",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"GENETIC","Intravenous infusion, single dose",[9],null,[21],{"name":22,"affiliation":23,"role":24},"LABRUNE Philippe, Prof","Hopital Antoine Beclere","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Genethon Clinical Development Department","CONTACT","00 33 (0)1 69 47 10 32","clinical_development@genethon.fr",[32,51,68,83],{"facility":33,"status":34,"city":35,"state":19,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Hopital Antoine BECLERE","RECRUITING","Clamart","92141","France","FR",{"type":40,"coordinates":41},"Point",[42,43],2.26692,48.80299,{"lat":43,"lon":42},[46,49],{"name":19,"role":28,"phone":47,"phoneExt":19,"email":48},"00 33 (0)1 45 37 42 72","philippe.labrune@abc.aphp.fr",{"name":50,"role":24,"phone":19,"phoneExt":19,"email":19},"Philippe LABRUNE, MD,PHD",{"facility":52,"status":34,"city":53,"state":19,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"ASST Papa Giovanni XXIII","Bergamo","24127","Italy","IT",{"type":40,"coordinates":58},[59,60],9.66721,45.69601,{"lat":60,"lon":59},[63,66],{"name":19,"role":28,"phone":64,"phoneExt":19,"email":65},"00390352674959","ldantiga@asst-pg23.it",{"name":67,"role":24,"phone":19,"phoneExt":19,"email":19},"Lorenzo D'Antiga, MD, PHD",{"facility":69,"status":34,"city":70,"state":19,"zip":71,"country":55,"countryCode":56,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Azienda Ospedaliera Universitaria Federico II","Naples","80131",{"type":40,"coordinates":73},[74,75],14.26811,40.85216,{"lat":75,"lon":74},[78,81],{"name":19,"role":28,"phone":79,"phoneExt":19,"email":80},"00390816132361","brunetti@tigem.it",{"name":82,"role":24,"phone":19,"phoneExt":19,"email":19},"Nicola Brunetti-Pierri, MD, PHD",{"facility":84,"status":34,"city":85,"state":19,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"AMC","Amsterdam","1105","Netherlands","NL",{"type":40,"coordinates":90},[91,92],4.88969,52.37403,{"lat":92,"lon":91},[95,98],{"name":19,"role":28,"phone":96,"phoneExt":19,"email":97},"0031-641476782","u.h.beuers@amc.uva.nl",{"name":99,"role":24,"phone":19,"phoneExt":19,"email":19},"Ulrich Beuers, MD, PHD",{"type":101,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100321561","gene-therapy-for-severe-crigler-najjar-syndrome-100321561",false,"NCT03466463","Gene Therapy for Severe Crigler Najjar Syndrome","A Phase I\u002FII, Open Label, Study to Evaluate Safety and Efficacy of an Intravenous Injection of GNT0003 (AAV Vector Expressing the UGT1A1 Transgene) in Patients With Severe Crigler-Najjar Syndrome Requiring Phototherapy","CareCN","Inclusion Criteria:\n\n* Patients with severe Crigler-Najjar syndrome resulting from a molecular confirmation of mutations in the UGT1A1 gene and requiring phototherapy\n* Male or female at least 9 years at the date of signature of informed consent\n* Patient able to give informed assent and\u002For consent in writing\n\nExclusion Criteria:\n\n* Patients who underwent liver transplantation\n* Patients with chronic hepatitis B or C\n* Patients infected with Human immunodeficiency virus (HIV)\n* Patients with significant underlying liver disease\n* Patients with significant encephalopathy\n* Participation in any other investigational trial during this trial\n* Patients unable or unwilling to comply with the protocol requirements","ALL","9 Years",{"count":113,"type":114},17,"ESTIMATED","INTERVENTIONAL",[117],"NA","This is a Phase 1\u002F2, multinational, open-label, study to evaluate the safety and efficacy of an intravenous infusion of GNT0003 in patients with Crigler-Najjar aged ≥10 years and requiring phototherapy. Patients will received a single administration of GNT0003 and will be followed for safety and efficacy of approximately 60 months (5 years):\n\n* a follow-up of approximately 12 months (48 weeks)\n* a long term follow-up of approximately 48 months (4 years), in order to be in line with the latest EMEA Guideline on follow-up of patients administered with gene therapy medicinal products, released on 22 Oct.2009 by the Committee for medicinal products for human use.",[120],"Crigler-Najjar Syndrome",[122,123],"Crigler-Najjar","Adeno Associated Virus","2023-03-23",{"date":126,"type":127},"2023-03-28","ACTUAL",{"date":129,"type":127},"2018-03-19",{"date":131,"type":114},"2030-03-30",{"name":5,"class":6},4]